Ceredex Value Advisors’s Lam Research LRCX Stock Holding History

Ceredex Value Advisors’s Portfolio LRCX Stock Details LRCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-314,949	Closed	-$42.2M	–	179
2025 Q3	$42.2M	Sell	314,949 -56,178	-15%	-$5.95M	0.98%	36
2025 Q2	$36.1M	Sell	371,127 -542,489	-59%	-$43M	0.78%	44
2025 Q1	$66.4M	Buy	913,616 +351,440	+63%	+$27.7M	1.45%	11
2024 Q4	$40.6M	Buy	+562,176	New	+$42.6M	0.82%	45

Other funds holding LRCX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ceredex Value Advisors's LRCX Position: Q4 2025 in Review

Ceredex Value Advisors sold out of Lam Research (LRCX) in Q4 2025, closing a stake of 314,949 shares — an estimated $42.2M sold.

Ceredex Value Advisors first reported a position in LRCX in Q4 2024 and held it in 4 quarters. The position peaked at $66.4M in Q1 2025. 2,390 funds tracked by Wall St. Rank hold LRCX as of Q4 2025.

Ceredex Value Advisors reported no remaining Lam Research position as of Q4 2025 after selling out during the quarter.
Ceredex Value Advisors sold 314,949 Lam Research shares in Q4 2025, an estimated $42.2M.
Ceredex Value Advisors first reported a position in Lam Research in Q4 2024 and held it in 4 quarters.
Ceredex Value Advisors's Lam Research position peaked at $66.4M in Q1 2025.
2,390 funds tracked by Wall St. Rank held Lam Research as of Q4 2025.

Based on Ceredex Value Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.